Compugen Ltd. (CGEN)
- Previous Close
1.9000 - Open
1.9000 - Bid 1.8800 x 200
- Ask 1.9100 x 300
- Day's Range
1.8700 - 1.9550 - 52 Week Range
0.5300 - 3.0300 - Volume
202,009 - Avg. Volume
597,195 - Market Cap (intraday)
170.382M - Beta (5Y Monthly) 2.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2100 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.33
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
cgen.comRecent News: CGEN
Performance Overview: CGEN
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CGEN
Valuation Measures
Market Cap
170.38M
Enterprise Value
121.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.95
Price/Book (mrq)
2.58
Enterprise Value/Revenue
3.62
Enterprise Value/EBITDA
-9.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-56.05%
Return on Assets (ttm)
-7.54%
Return on Equity (ttm)
-26.19%
Revenue (ttm)
33.46M
Net Income Avi to Common (ttm)
-18.75M
Diluted EPS (ttm)
-0.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
50.69M
Total Debt/Equity (mrq)
2.06%
Levered Free Cash Flow (ttm)
-51.05M